Superdrol

Methyldrostanolone (2α,17α-dimethyl-5α-androstan-3-one-17β-ol) is a C17-alpha-alkylated derivative of Drostanolone (Masteron). Originally marketed as a "prohormone" in the early 2000s to circumvent regulatory classification, it is in fact a potent active anabolic steroid — and one of the most powerful orals ever produced. Its anabolic:androgenic ratio is approximately 400:20, placing it in a category of anabolic potency that rivals or exceeds injectable compounds like Trenbolone, delivered in a convenient oral tablet.

Superdrol's mechanism involves high-affinity androgen receptor binding with exceptionally strong anabolic signaling in skeletal muscle. It does not aromatize to estrogen, carries no progestogenic activity, and produces zero water retention. The result is a compound that generates dramatic dry mass gains — lean tissue accrual with a hard, full, vascular appearance from the first week of administration. Its DHT-derivative status means it also carries Masteron-like anti-estrogenic activity, contributing to a dense, grainy aesthetic. Strength gains on Superdrol are pronounced and rapid, often exceeding what researchers experience with Anadrol despite the absence of water-mediated weight gain.

Superdrol is the oral of choice for researchers who want maximum dry mass in minimum time. It compresses several weeks' worth of lean gains into a 3–4 week window, with results that are visually dramatic and largely retainable post-cycle (since there is no water component to shed). The compound's reputation as one of the most powerful orals is well-earned — many experienced researchers rate it above Anadrol for pound-for-pound lean tissue accrual.

This is strictly an advanced compound. It is not appropriate for novice researchers under any circumstances. Superdrol's potency comes with commensurate hepatotoxicity — it is one of the most liver-toxic orals available, and liver stress can escalate rapidly. Experienced researchers typically limit Superdrol to 3–4 week runs as a kickstart or finisher within a longer injectable cycle. It pairs well with a Testosterone base and liver-support supplementation is non-negotiable.

Methyldrostanolone has a half-life of approximately 8–9 hours, supporting twice-daily dosing. Research dosages range from 10–30 mg daily, with 20 mg being the most common dose for experienced researchers. At 10 mg, results are already significant — this is not a compound that requires aggressive dosing to produce effects. TUDCA (500–1000 mg daily) and NAC (600–1200 mg daily) are mandatory liver-support agents during administration. Cycle length must not exceed 4 weeks — and many researchers run it for only 3. Pre- and post-cycle liver panels (ALT, AST, GGT, bilirubin) are essential. Lethargy during the final week of a Superdrol run is common and is typically a hepatic stress signal indicating it is time to discontinue. Blood pressure monitoring is also advisable.